CD274 and neoplasm: The resulting nanoplatform, termed VLN@Axi, successfully achieved CRISPR/Cas9-based PD-L1 knockout in cancer cells, effectively disrupting the PD-1/PD-L1 pathway and reinvigorating the exhausted T cells to suppress the tumor.